Assessment of childhood maltreatment in pharmacotherapy trials for schizophrenia.

Abstract

Schizophrenia spectrum disorders (SSD) are among the leading global causes of disability, owing to chronic trajectories and high rates of treatment resistance. Antipsychotic medications are generally effective, but in up to a third of individuals with an acute episode, their symptoms show insufficient treatment response, underscoring the need to identify predictors of poor outcomes.